title: Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide.
abstract: Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported. Here, we report on a 9-year-old female with rhabdomyosarcoma who developed severe SOS after receiving chemotherapy consisting of vincristine, actinomycin-D, and a moderate dose of cyclophosphamide. She was treated successfully with defibrotide without sequelae to the liver.
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Aery
authors.initials: A
authors.lastname: Choi
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Young Kyung
authors.initials: YK
authors.lastname: Kang
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Sewon
authors.initials: S
authors.lastname: Lim
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Dong Ho
authors.initials: DH
authors.lastname: Kim
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Jung Sub
authors.initials: JS
authors.lastname: Lim
authors.affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
authors.forename: Jun Ah
authors.initials: JA
authors.lastname: Lee
mesh_terms: D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage*; D012208:Rhabdomyosarcoma / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014750:Vincristine / Q000009:adverse effects
chemical_list: D011089:Polydeoxyribonucleotides; D003609:Dactinomycin; C036901:defibrotide; D014750:Vincristine; D003520:Cyclophosphamide
keywords: Defibrotide; Hepatic veno-occlusive disease; Rhabdomyosarcoma